1. Home
  2. CAPR vs MTRX Comparison

CAPR vs MTRX Comparison

Compare CAPR & MTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • MTRX
  • Stock Information
  • Founded
  • CAPR 2005
  • MTRX 1984
  • Country
  • CAPR United States
  • MTRX United States
  • Employees
  • CAPR N/A
  • MTRX N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • MTRX Engineering & Construction
  • Sector
  • CAPR Health Care
  • MTRX Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • MTRX Nasdaq
  • Market Cap
  • CAPR 453.9M
  • MTRX 373.0M
  • IPO Year
  • CAPR N/A
  • MTRX 1990
  • Fundamental
  • Price
  • CAPR $11.66
  • MTRX $13.79
  • Analyst Decision
  • CAPR Strong Buy
  • MTRX Strong Buy
  • Analyst Count
  • CAPR 8
  • MTRX 1
  • Target Price
  • CAPR $33.75
  • MTRX $20.00
  • AVG Volume (30 Days)
  • CAPR 3.0M
  • MTRX 187.8K
  • Earning Date
  • CAPR 08-06-2025
  • MTRX 05-07-2025
  • Dividend Yield
  • CAPR N/A
  • MTRX N/A
  • EPS Growth
  • CAPR N/A
  • MTRX N/A
  • EPS
  • CAPR N/A
  • MTRX N/A
  • Revenue
  • CAPR $17,363,588.00
  • MTRX $742,408,000.00
  • Revenue This Year
  • CAPR $258.96
  • MTRX $9.98
  • Revenue Next Year
  • CAPR $8.02
  • MTRX $20.42
  • P/E Ratio
  • CAPR N/A
  • MTRX N/A
  • Revenue Growth
  • CAPR N/A
  • MTRX N/A
  • 52 Week Low
  • CAPR $3.52
  • MTRX $8.61
  • 52 Week High
  • CAPR $23.40
  • MTRX $15.75
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 50.35
  • MTRX 61.92
  • Support Level
  • CAPR $9.65
  • MTRX $13.31
  • Resistance Level
  • CAPR $10.56
  • MTRX $14.10
  • Average True Range (ATR)
  • CAPR 1.21
  • MTRX 0.39
  • MACD
  • CAPR -0.02
  • MTRX 0.02
  • Stochastic Oscillator
  • CAPR 70.08
  • MTRX 74.37

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About MTRX Matrix Service Company

Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.

Share on Social Networks: